Guidance on Format of the RMP in the EU in Integrated Format
Splendris Pharmaceuticals GmbH Benazeprilhydrochloride “Splendris” RMP v. 1.0 02 October 2017 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Hypertension, is a long term medical condition in which the blood pressure is persistently elevated. Usually it does not cause symptoms, but it is a major risk factor for coronary artery disease, stroke, heart failure, peripheral vascular disease, vision loss, and chronic kidney disease. It is the most important preventable risk factor for premature death worldwide. Hypertension results from a complex interaction of genes and environmental factors like rising age, high salt intake, lack of exercise, obesity, or depression. As mechanisms the most evident are disturbance in the kidneys’ salt and water handling and/or abnormalities of the sympathic nervous system. Approximately one billion adults worldwide are affected. In Europe hypertension occurs in 30-43% of adult people, 1 to 5% of children and adolescents and 0.2 to 3% of newborns. Treatment options include changes in lifestyle, like dietary changes, physical exercise, weight loss, and medications, like ACE-inhibitors or calcium channel blockers. VI.2.2 Summary of treatment benefits The benazepril formulation described is a generic equivalent to the innovator formulation. Clinical studies have been performed with benazepril in hypertensive patients showing that blood pressure is significantly reduced. When given with other blood lowering agents e.g. betablockers, the antihypertensive effect is greater than for benazepril alone. In different studies, it has been shown that benazepril was similar or superior in lowering blood pressure and reducing proteinuria or myocardial ischaemia when compared with hydrochlorthiazide, metoprolol, captopril, nifedipine or nitrendipine.
[Show full text]